168 related articles for article (PubMed ID: 32591201)
1. The drug treatment research of gastrointestinal cancer in China.
Ren C; Xu RH
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e3-e6. PubMed ID: 32591201
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor (Her-2) in gastric and colorectal adenocarcinoma.
Shabbir A; Qureshi MA; Mirza T; Khalid AB
J Pak Med Assoc; 2017 Jul; 67(7):1085-1090. PubMed ID: 28770892
[TBL] [Abstract][Full Text] [Related]
3. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
4. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
Almquist DR; Ahn DH; Bekaii-Saab TS
BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
[TBL] [Abstract][Full Text] [Related]
5. Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma.
Sacdalan DB; Mendoza MJ; Vergara JP; Catedral LI; Ting FI; Leones LM; Berba CM; Sacdalan DL
Med Oncol; 2020 Nov; 37(11):106. PubMed ID: 33135102
[TBL] [Abstract][Full Text] [Related]
6. Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors.
Sun J; Zheng Y; Mamun M; Li X; Chen X; Gao Y
Biomed Pharmacother; 2020 Sep; 129():110504. PubMed ID: 32768978
[TBL] [Abstract][Full Text] [Related]
7. Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
Chen C; Di Bartolomeo M; Corallo S; Strickler JH; Goyal L
Am Soc Clin Oncol Educ Book; 2020 May; 40():161-173. PubMed ID: 32421451
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatment for metastatic colorectal cancer in the era of precision medicine.
Sandhu J; Lavingia V; Fakih M
J Surg Oncol; 2019 Apr; 119(5):564-582. PubMed ID: 30802315
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.
Smyth E; Thuss-Patience PC
Oncol Res Treat; 2018; 41(5):272-280. PubMed ID: 29705787
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer?
Eisterer W; Prager G
Cardiovasc Intervent Radiol; 2019 Sep; 42(9):1213-1220. PubMed ID: 31270570
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
12. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
[TBL] [Abstract][Full Text] [Related]
13. [Antiangiogenic therapy for gastrointestinal tumors].
Lakatos G; Tulassay Z
Orv Hetil; 2008 Dec; 149(49):2317-24. PubMed ID: 19042183
[TBL] [Abstract][Full Text] [Related]
14. [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors].
Obermannova R
Klin Onkol; 2017; 30(Supplementum3):50-54. PubMed ID: 29239193
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for esophageal, gastric and colorectal cancers.
Treat Guidel Med Lett; 2006 Aug; 4(48):55-60. PubMed ID: 16912662
[No Abstract] [Full Text] [Related]
16. Predictive factors to targeted treatment in gastrointestinal carcinomas.
Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
18. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Lote H; Cafferkey C; Chau I
Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
[TBL] [Abstract][Full Text] [Related]
19. Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer.
Lu Z; Zou J; Hu Y; Li S; Zhou T; Gong J; Li J; Zhang X; Zhou J; Lu M; Wang X; Peng Z; Qi C; Li Y; Li J; Li Y; Zou J; Du X; Zhang H; Shen L
JAMA Netw Open; 2019 Jul; 2(7):e197621. PubMed ID: 31339548
[TBL] [Abstract][Full Text] [Related]
20. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
